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Abstract
Purpose—4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), one of the most prevalent
and procarcinogenic compounds in tobacco, is bioactivated by respiratory cytochrome P450
(CYP) 2A13, forming DNA adducts and initiating lung cancer. CYP2A13 inhibition offers a novel
strategy for chemoprevention of tobacco-associated lung cancer.
Methods—Twenty-four analogs of a 4-benzylmorpholine scaffold identified by high throughput
screening were evaluated for binding and inhibition of both functional human CYP2A enzymes,
CYP2A13 and the 94%-identical hepatic CYP2A6, whose inhibition is undesirable. Thus,
selectivity is the major challenge in compound design.
Results—A key feature resulting in CYP2A13-selective binding and inhibition was substitution
at the benzyl ortho position, with three analogs being >25-fold selective for CYP2A13 over
CYP2A6.
Conclusions—Two such analogs were negative for genetic and hERG toxicities and
metabolically stable in human lung microsomes, but displayed rapid metabolism in human liver
and in mouse and rat lung and liver microsomes, likely due to CYP2B-mediated degradation. A
specialized knockout mouse mimicking the human lung demonstrates compound persistence in
lung and provides an appropriate test model. Compound delivered by inhalation may be effective
in the lung but rapidly cleared otherwise, limiting systemic exposure.
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The cytochrome P450 (CYP) superfamily of heme-containing monooxygenase enzymes
metabolizes a variety of exogenous and endogenous substrates which can be manipulated for
therapeutic benefit.(1) For example, the selective inhibition of androgen and estrogen
biosynthetic CYP enzymes has afforded significant progress in the treatment of prostate and
breast cancer.(2, 3) In contrast, inhibition of xenobiotic-metabolizing CYP enzymes has
often been viewed as an unproductive approach to drug discovery due to selectivity issues
expected for such agents. Despite this, a selective CYP3A4 inhibitor has now been
deliberately developed from retonavir for explicit use as pharmacokinetic booster.(4-6)
Similarly, inhibition of CYP enzymes involved in the activation of procarcinogens can offer
chemopreventative opportunities; such is the case in tobacco-associated lung cancer. Lung
cancer is the leading cause of all cancer-related deaths,(7) and >80% of all lung cancer
incidence results from tobacco use.(8) According to the CDC, 69% of tobacco users desire
to quit,(9) but due to the addictive properties of nicotine and ineffectiveness of current
tobacco cessation techniques, only 5% of users successfully cease tobacco use.(10) A
complementary strategy to reduce lung cancer prevalence is to decrease the in vivo
formation of tobacco carcinogens. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
is one of the most prevalent and, when activated, one of the most carcinogenic compounds
in tobacco. NNK is selectively biotransformed by cytochrome P450 2A13 (CYP2A13) in the
respiratory tract to form one of two diazonium ions that generate DNA adducts in genes like
p53 and ras and can initiate lung cancer.(11, 12)
A CYP2A13 inhibitor, therefore, offers a novel therapeutic strategy to reducing the risk of
lung cancer in tobacco users. This target is validated by CYP2A13 polymorphisms and
animal studies. Tobacco users with natural-occurring polymorphisms resulting in reduced
CYP2A13 activity exhibit normal physiological characteristics but have a decreased risk for
lung adenocarcinoma.(13, 14) Mouse studies have substantiated the role of the respiratory
tract(15) and the CYP2A13 ortholog, CYP2A5,(16) in NNK bioactivation. NNK-induced
tumors were also reduced from 70% to 5% in rats with the known pan-CYP2A inhibitor,
phenethyl isothiocyanate (PEITC)(17). Finally, CYP2A13 inhibition has been correlated to a
decrease in NNK bioactivation and an increase in NNK clearance via nontoxic
glucuronidation and excretion.(18) Thus, once CYP2A13 is inhibited, an increased amount
of NNK is cleared via nontoxic, non-carcinogenic metabolites.
The most significant difficulty in developing effective P450 inhibitors arises in designing
selectivity for an individual enzyme in this superfamily. In contrast to biosynthetic CYP
enzymes like aromatase that are fairly specific for their substrates, most xenobiotic-
metabolizing CYP enzymes have evolved to recognize and act upon a wide range of
chemically diverse small molecules. This is often accomplished via large and/or flexible
active sites that frustrate structure-based predictions of ligand binding. For example, the
large active site of the hepatic CYP3A4 enzyme is responsible for the metabolism of
34%(19) of clinically used drugs, so that even a selective CYP3A4 inhibitor such as the
pharmacokinetic booster cobicistat can frequently have substantial adverse drug-drug
interactions. Extrahepatic CYP enzymes such as CYP2A13 that are much less involved in
drug metabolism are also much less likely to have adverse effects, so long as the inhibitors
are selective and do not inhibit other CYP enzymes.
The largest challenge in developing CYP2A13 inhibition as a chemopreventative approach
is likely to be nonselective inhibition of the only other functional human CYP2A enzyme,
the 94% identical hepatic CYP2A6. CYP2A6 shares a number of substrates and inhibitors
with CYP2A13, but is primarily involved in vivo in the metabolism of drugs in systemic
circulation, including nicotine, and does not effectively bioactivate NNK or contribute to
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DNA adduct formation in the respiratory tract(20, 21). The emphasis of this work was the
identification and evaluation of small molecule inhibitors of CYP2A13 that are selective vs.
CYP2A6. High throughput screening was initially used to identify a 4-benzylmorpholine
scaffold that might have the potential to effectively and selectively inhibit CYP2A13. A
library of twenty-four 4-benzylmorpholine analogs was then generated. Analysis of
differential binding to and inhibition of recombinant, purified CYP2A13 and CYP2A6
enzymes in vitro led to the determination of structure-activity relationships for the 4-
benzylmorpholine scaffold with the human CYP2A enzymes that may form the basis for
future studies toward lung cancer chemoprevention.
MATERIALS AND METHODS
Protein Expression and Purification
Human CYP2A enzymes were truncated, His-tagged, expressed, and purified as previously
described.(22, 23) Rat cytochrome P450 oxidoreductase (POR) was purified using published
procedures.(24)
High Throughput Screening
The spectral shift assay (vide infra) reflecting interactions of compounds with CYP2A13
was adapted to HTS format for screening ChemBridge library of 35,200 compounds. Each
384-well screening plate contained 320 library compounds (20 uM in 0.71% DMSO) and a
set of standards comprising 32 wells: 16-wells each of 0.71% DMSO (negative control), and
16-wells of ositive control (30 μM phenethyl isothiocyanate or PEITC). Purified CYP2A13
(3 μM) was added to all the wells of the assay plates and the protein/compound mixtures
were allowed to equilibrate at room temperature for 5 min. The plates were read on
SpectraMax (Molecular Devices, CA) at 385 nm and 420 nm. Primary screen actives were
identified as compounds that resulted in difference of 0.1 (plate median + 5 standard
deviation) in raw absorbance values at 385 nm and 420 nm.
Spectral Ligand Binding Assay
Ligand binding was monitored by following spectral changes upon titration with increasing
concentrations of ligand and the data analyzed as previously described,(25) except that all
compounds were dissolved in DMSO. However, the imidazole-containing compounds
bound tightly enough to require a reduction in protein concentration to 0.1 μM, use of 5 cm
path length cuvette, and analysis with the tight binging equation as described previously.(26)
Coumarin Metabolism Assay(27, 28)
The 50 pmol of purified CYP2A enzyme was reconstituted with 200 pmol of POR by
coincubation on ice for 50 minutes before addition to the reaction samples containing buffer
(50 mM Tris, HCl, pH 7.4, 5 mM MgCl), 0-90 μM coumarin substrate, and varying inhibitor
concentrations. Samples were warmed for 3 minutes at 37 °C before addition of 1 mM
NADPH to initiate the 250 μl reaction. Catalysis proceeded for 10 min before termination
with 75 μl of 20% trichloroacetic acid (TCA) to precipitate protein. TCA was added to all
standard samples prior to NADPH addition. Additional buffer (200 μl) and 100 μl of 1.6 M
glycine were added to each tube before centrifugation at 4,400 × g for 6 minutes. CYP2A6
samples required an additional 5-fold dilution due to detector limitations. Formation of the
7-hydroxycoumarin metabolite was monitored via fluorescence detection with an excitation
wavelength of 355 nm and an emission wavelength of 460 nm following chromatographic
separation with a reverse phase C18 column on an HPLC. A mobile phase of 40% methanol
and 0.12% acetic acid was used with a flow rate of 0.8 mL min−1. A small amount of a
second product, likely the 3,4-epoxide metabolite,(29) was observed at the lowest substrate
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concentration (5 μM) in the absence of inhibitor and automated outlier exclusion analysis
with the data analysis software Prism 5 was used to handle this data point. Prism 5 was also
used for data analysis of the six substrate and four inhibitor concentrations resulting in the
kcat and Km values that were used to determine the mode of inhibition and ultimately Ki
value for each compound with the CYP2A enzymes with the appropriate formula shown
below. Competitive inhibition:  and  where Km Obs is the
observed Km, [I] is the inhibitor concentration, Ki is the inhibition constant, and [S] is the
substrate concentration. Mixed model inhibition: , , and
Inhibitors
The benzylmorpholine analogs 4-(2-fluorobenzyl)morpholine (2), 4-(2-
chlorobenzyl)morpholine (3), 4-(2-bromobenzyl)morpholine (4), 4-(2-
methylbenzyl)morpholine (5), 4-(2-chloro-6-fluorobenzyl)morpholine (7), 4-(2,6-
dichlorobenzyl)morpholine (8), 4-(2,3-dichlorobenzyl)morpholine (12), 4-(2,4-
dichlorobenzyl)morpholine (13), 4-(2,3-dichlorobenzyl)-2,6-dimethylmorpholine (14), 4-
(naphthalen-1-ylmethyl)morpholine (15), and 4-(2-chlorobenzyl)thiomorpholine (16) were
purchased from ChemBridge. The stereochemistry of the methyl substituents on 14 is
unknown but the supplier indicates it is believed to be racemic.
Benzylmorpholine (1),(30) 4-(2-ethylbenzyl)morpholine (6), 4-(2-chloro-6-
methylbenzyl)morpholine (9), 4-(3-chlorobenzyl)morpholine (10), 4-(4-
chlorobenzyl)morpholine (11),(31) 1-(2-chlorobenzyl)-4-methylpiperazine (17), 1-(2,6-
dichlorobenzyl)-4-methylpiperazine (18), 4-(thiophen-2-ylmethyl)morpholine (19), 4-((3-
chlorothiophen-2-yl)methyl)morpholine (20), 1-(2-chlorobenzyl)-4-methylpiperazine (21),
and 1-(2,6-dichlorobenzyl)-4-methylpiperazine (22) were synthesized in a MiniBlock®
apparatus using published protocols.(32) Synthesis of 4-(1-(2-
chlorophenyl)ethyl)morpholine (23) followed the same procedure(32) in a reaction flask,
which resulted in a racemic mixture. Production of 1-(2-chlorobenzyl)-1H-imidazole (17)
and 1-(2,6-dichlorobenzyl)-1H-imidazole (18) also used previously established methods.
(33) 4-(2-Chlorophenethyl)morpholine (24) was synthesized by combining 2-
chlorophenethyl bromide (1.3 mmol), morpholine (1.0 mmol), potassium carbonate
(2.0mmol) in 4 mL of dry acetonitrile and stirred at 80 °C overnight. Product was extracted
with ethyl acetate, washed with sodium bicarbonate, dried with magnesium sulfate, and
solvent was removed under vacuum.
Compound analysis by 1H and 13C NMR was performed on a Bruker 400 MHz instrument.
TopSpin and MestReNova were used to analyze the NMR data, which is given in ppm.
LCMS was completed with a Waters 2795 HPLC and Waters LCT Premier TOF mass
spectrometer. Compound purity was determined to be >95% by HPLC reverse phase
chromatography. The HPLC mobile phase consisted of a 5-95% organic gradient with
solvents A (99% water (pH 9.8 ammonium hydroxide), 1% acetonitrile) and B (99%
acetonitrile, 1% water) and a flow rate of 0.6 mL/min.
4-(2-Ethylbenzyl)morpholine (6)—The synthesis afforded a clear oil with a yield of
77.9 mg (35%). HRMS (m/z): [M+H] 206.15; calculated 206.15. 1H NMR (400 MHz,
chloroform-d) δ 7.35 - 7.12 (m, 4H), 3.79 - 3.67 (m, 4H), 3.52 (s, 2H), 2.78 (q, J = 7.5 Hz,
2H), 2.48 (dd, J = 5.8, 3.7 Hz, 4H), 1.27 (t, J = 7.5 Hz, 3H).
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4-(2-Chloro-6-methylbenzyl)morpholine (9)—The synthesis yielded 55.6 mg (27%) of
an oily product. HRMS (m/z): [M+H] 226.10; calculated 226.09. 1H NMR (400 MHz,
chloroform-d) δ 7.31 - 7.19 (m, 1H), 7.14 - 7.07 (m, 2H), 3.73 - 3.60 (m, 6H), 2.57 - 2.49
(m, 4H), 2.47 (s, 3H).
4-(3-Chlorobenzyl)morpholine (10)—The synthesis resulted in 25 mg (44.7%) of a
yellow oil. HRMS (m/z): [M+H] 212.09; calculated 212.08. 1H NMR (400 MHz,
chloroform-d) δ 7.37 (d, J = 2.0 Hz, 1H), 7.33 - 7.05 (m, 3H), 3.81 - 3.62 (m, 4H), 3.49 (s,
2H), 2.46 (dd, J = 5.7, 3.7 Hz, 4H).
1-(2-Chlorobenzyl)-1H-imidazole (17)—The synthesis produced 30.7 mg (17%) of a
yellow oil. HRMS (m/z): [M+H] 193.05; calculated 193.05. 1H NMR (400 MHz,
chloroform-d) δ 7.57 (s, 1H), 7.41 (dd, J = 7.7, 1.6 Hz, 1H), 7.33 - 7.18 (m, 2H), 7.10 (s,
1H), 6.99 - 6.88 (m, 2H), 5.23 (s, 2H).
1-(2,6-Dichlorobenzyl)-1H-imidazole (18)—The resulting synthetic product was a
yellow oil with a yield of 171.3 mg (75%). HRMS (m/z): [M+H] 227.01; calculated
227.01. 1H NMR (400 MHz, chloroform-d) δ 7.61 (s, 1H), 7.39 - 7.24 (m, 2H), 7.17 (dd, J =
8.8, 7.4 Hz, 1H), 6.98 (d, J = 14.9 Hz, 2H), 5.33 (s, 2H).
4-(Thiophen-2-ylmethyl)morpholine (19)—The synthesis resulted in 130 mg (71%) of
a yellow oil. HRMS (m/z): [M+H] 184.08; calculated 184.07. 1H NMR (400 MHz,
chloroform-d) δ 7.24 (dd, J = 5.0, 1.3 Hz, 1H), 6.94 (ddd, J = 7.4, 4.4, 2.2 Hz, 2H), 3.75 -
3.68 (m, 6H), 2.53 - 2.45 (m, 4H).
4-((3-Chlorothiophen-2-yl)methyl)morpholine (20)—The synthesis afforded a yellow
oil with a yield of 150 mg (70%). HRMS (m/z): [M+H] 218.04; calculated 218.03. 1H NMR
(400 MHz, Chloroform-d) δ 7.23 (d, J = 5.3 Hz, 1H), 6.87 (d, J = 5.3 Hz, 1H), 3.85 - 3.65
(m, 6H), 2.67 - 2.38 (m, 4H).
1-(2-Chlorobenzyl)-4-methylpiperazine (21)—The synthesis of 21 yielded a yellow oil
with a yield of 168.8 mg (75%). HRMS (m/z): [M+H] 225.12; calculated 225.11. 1H NMR
(400 MHz, chloroform-d) δ 7.49 (dd, J = 7.5, 1.9 Hz, 1H), 7.36 (dd, J = 7.7, 1.5 Hz, 1H),
7.31 - 7.15 (m, 2H), 3.65 (s, 2H), 2.58 (s, 4H), 2.48 (s, 4H), 2.31 (s, 3H).
1-(2,6-Dichlorobenzyl)-4-methylpiperazine (22)—The synthesis resulted in 184.1 mg
(71.0%) of an amorphous solid. HRMS (m/z): [M+H] 259.08; calculated 259.07. 1H NMR
(400 MHz, chloroform-d) δ 7.26 (d, J = 8.0 Hz, 2H), 7.09 (dd, J = 8.5, 7.5 Hz, 1H), 3.73 (s,
2H), 2.60 (s, 5H), 2.43 - 2.34 (m, 3H), 2.24 (s, 3H).
4-(1-(2-Chlorophenyl)ethyl)morpholine (23)—The synthesis afforded a yield of 48.1
mg (21%) of an oil. HRMS (m/z): [M+H] 226.10; calculated 226.09. 1H NMR (400 MHz,
chloroform-d) δ 7.60 (dd, J = 7.8, 1.8 Hz, 1H), 7.35 (dd, J = 7.9, 1.4 Hz, 1H), 7.31 - 7.23 (m,
1H), 7.18 (dd, J = 7.7, 1.8 Hz, 1H), 3.89 (q, J = 6.6 Hz, 1H), 3.72 (dt, J = 5.8, 3.6 Hz, 4H),
2.57 (dt, J = 9.8, 4.6 Hz, 2H), 2.41 (ddd, J = 11.3, 5.8, 3.3 Hz, 2H), 1.31 (d, J = 6.6 Hz, 3H).
4-(2-Chlorophenethyl)morpholine (24)—The synthesis resulted in 129 mg (58%) of a
yellow oil. HRMS (m/z): [M+H] 226.10; calculated 226.09. 1H NMR (400 MHz,
Chloroform-d) δ 7.39 - 7.03 (m, 4H), 3.88 - 3.62 (m, 4H), 3.00 - 2.83 (m, 2H), 2.65 - 2.40
(m, 6H).
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For compounds evaluated in binding and inhibition studies, solubility was evaluated in
buffer by monitoring turbidity in the UV/Vis cuvettes. For test compounds advanced to
toxicity and metabolic stability studies, aqueous solubility was explicitly determined in
phosphate-buffered saline at pH 7.4 using the shake-flask incubation method (24 hours at
room temperature). The mean solubilities of 4-(2-chlorobenzyl)morpholine (3) and 4-(2-
chloro-6-fluorobenzyl)morpholine (7) thus determined were 180 and 184 μM, respectively.
These values are near the 200 μM maximum for the assay conditions and established that
solubility is generally high for these compounds.
Metabolic Stability Phenotyping with recombinantly expressed CYPs
The half-lives of select compounds were determined with a panel of recombinantly
expressed cytochrome P450 enzymes including 1A2, 2C9, 2D6, 3A4, and 2C19 (Pan Vera
Corp., Madison, WI) and 2C8 and 2B6 (BD Gentest, San Jose, CA) in a plate assay format.
Incubations consisted of 100 pmol/ml of one of the above P450 enzymes and 1 μM of the
inhibitor in 0.1 mM potassium phosphate, pH 7.4, 3.33 mM MgCl2 in a total of 200 μl.
These solutions were prewarmed to 37 °C for 10 min. prior to initiating the reaction with the
addition of 1 mM NADPH regenerating system (NADP+, glucose-6-phosphate, glucose-6-
phosphate dehydrogenase in 0.1 mM postassium phosphate). Aliquots of 25 μl were
removed at various times (0, 5, 10, 20, 30, 45 min) and immediately quenched by addition to
75 μl of methanol containing buspirone as an internal standard. Controls substituted
potassium phosphate buffer for the NADPH-generating system. Samples were centrifuged at
3,000 rpm and 50 μl of the supernatant diluted 1:1 with water. Mass spectrometry was used
to determine the peak areas for the inhibitors and internal standard, from which the peak
area ratios were calculated. The ln of this ratio vs. time gave the slope, which was converted
to T1/2. All reactions were run in duplicate.
Metabolic Stability in Rat, Mouse, and Human Lung and Liver Microsomes
The half-lives of select compounds were determined with microsomes from pools of male
B6C2F1 mouse liver, male B6C2F1 mouse lung, male Sprague-Dawley rat liver, male
Sprague-Dawley rat lung, human liver and human lung (Xenotech) and from transgenic B6
Cyp2a(4/5)bgs-Null mice (35) as a gift from Dr. Xinxin Ding (Wadsworth Center). In each
case 1.0 or 0.1 mg protein/ml, respectively, was added to 50 mM potassium phosphate
buffer, pH 7.4, with 3 mM MgCl2, and 1 mM EDTA with and without the NADPH-
generating system and 1 μM test compound (in 0.1% DMSO) to a total of 200 μl volume in
a 96-well plate using a Tecan Liquid Handling System at 37 °C in triplicate. Reactions were
initiated by the addition of the NADPH-generating system (1 mM NADP, pH 7.4, 5 mM
glucose-6-phosphate, and 1 U/ml glucose-6-phosphate dehydrogenase) and were terminated
at 0, 5, 10, and 20 minutes by the addition of 200 μl acetonitrile containing 0.1 μM
antipyrene (v/v). Samples were centrifuged at 920 × g for 10 min. at 10 °C and the
supernatant analyzed by LC/MS/MS. The time course of disappearance of the parent
compound was evaluated as a single exponential decay and used to determine the rate
constant of elimination values (kel, min−1) and converted to T1/2. The rate constant of
elimination was used to calculate the in vitro intrinsic clearance, Clint microsomes:
Clint-microsomes (μl/min/mg protein) = kel(min−1) × incubation volume (μl)/mg protein per
incubation.
RESULTS AND DISCUSSION
To initiate a discovery effort to identify potential scaffolds for selective inhibitors of human
CYP2A13, a high throughput screening campaign was conducted. A cuvette-based assay
based on UV/Vis absorbance changes upon ligand binding (described in Methods) was
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miniaturized and adapted for screening in 384-well format. Fig. 1 summarizes data from the
high throughput screen. An average Z’ score of 0.89 ± 0.08 was obtained from positive
(CYP2A13+PEITC) and negative control wells (CYP2A13+DMSO), which is an acceptable
dynamic range for a high throughput screening assay. Primary screening of 35,200
Chembridge library compounds resulted in a high hit rate of 1.4%. This relatively high hit
rate likely reflects the nature of the target. Xenobiotic-metabolizing cytochrome P450
enzymes have evolved to be promiscuous and would be expected to bind a higher number of
library compounds than most proteins. Of the 508 primary screen actives that were
repurchased and tested for binding with both CYP 2A13 and the 94% identical CYP2A6, 93
compounds were found to bind to CYP2A13 specifically (ΔAbs 385-419 nm > 0.2)
compared with CYP2A6 (ΔAbs 385-419 nm <0.03). Several CYP2A13-specific scaffolds
were tentatively identified. Analysis of few representative compounds at varying
concentrations resulted in identification of 4-(2-chloro-6-fluorobenzyl) morpholine as a true
selective ligand of CYP2A13 vs. CYP2A6. As shown in the Figure 1D, 4-(2-chloro-6-
fluorobenzyl) morpholine bound CYP2A13 with a Kd of approximately 2 μM, but caused no
spectral shift with 2A6.
Thus, this study was designed to evaluate 4-benzylmorpholine as a potential scaffold for
CYP2A13-selective inhibitors. A pilot library of twenty-four 4-benzomorpholine analogs
was designed to obtain structure–activity relationships in the parent scaffold and constructed
using standard chemistry. Both ligand binding and enzyme inhibition were used to evaluate
the interactions of these analogs with purified, recombinant CYP2A enzymes. Ligand
binding is conveniently measured by observing, in difference mode, shifts in the electronic
absorbance spectrum as ligands enter the active site. Inhibition was measured as the
disruption of hydroxylation of the prototypical CYP2A substrate coumarin to 7-
hydroxycoumarin. The resulting Kd and Ki values are shown in Table 1, along with the
selectivity, as calculated by the ratio of the CYP2A6 value to the CYP2A13 value.
Titration of CYP2A13 and CYP2A6 with most of the 4-benzylmorpholine analogs revealed
binding primarily resulted in type I spectral shifts in the UV/Vis difference spectra, as
indicated by (I) in the Kd column of Table 1. This transition from the Fe hexacoordinate low
spin, water bound state (λmin = ~420 nm) to a pentacoordinate high spin state (λmax = ~385
nm), reflects ligand binding in the P450 active site so as to displace the water molecule
normally coordinated to the ferric heme iron in the resting state of the enzyme. In contrast,
binding of compounds 1, 10, and 18 to CYP2A6 and binding of compounds 16 and 17 to
both CYP2A13 and CYP2A6 resulted in difference spectra with decreases in absorbance at
393-413 nm and increases in absorbance at ~433 nm called type II spectra shifts. Such
transitions upon ligand binding indicate conversion from the hexacoordinate, low-spin,
water-bound iron to a hexacoordinate form in which the ligand typically coordinates to the
iron via its lone pair electrons. Thus, the spectra of these compounds give an indication of
the orientation of some ligands with respect to the catalytic heme iron. Some compounds
yielded very limited or no spectral shifts with CYP2A6 which indicates the compound is
either not binding or not binding in the active site in such a way that displaces water on the
heme iron, which are desirable features of a CYP2A13-selective inhibitor.
Inhibition studies indicated that all but seven 4-benzylmorpholine analogs were purely
competitive inhibitors of both CYP2A13 and CYP2A6. However, mixed inhibition resulting
from inhibitor binding to both the free and substrate-bound form of the enzyme was
observed for compounds 14, 16, and 17 with CYP2A13, and compounds 1, 6, 15, and 18
with CYP2A6. In all cases the alpha value was greater than 1, indicating a preference for
inhibitor binding to free enzyme over the enzyme/substrate complex. Compounds 6 and 14
had the strongest preference for the free enzyme with alpha values of 13.3 and 19.6,
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respectively, while the remaining compounds demonstrating mixed inhibition had alpha
values between 2.0-3.9.
Ortho (C2) substitution on the benzene ring
The parent, unsubstituted 4-benzylmorpholine compound (1), demonstrated a type I spectral
shift with CYP2A13 (Kd = 116 μM), but a definitive Kd value could not be determined for
CYP2A6. Binding of (1) to CYP2A6 resulted in spectral shifts at concentrations that
converted from type I to type II over the course of the titration and were consistent with a Kd
≥300 μM. Not only did this parent compound bind poorly, it was also a poor inhibitor of
both CYP2A13 (Ki = 477 μM) and CYP2A6 (Ki = 675 μM) and was not selective for either
enzyme.
Addition of a fluorine atom on the benzene ring (2) would be expected to maintain the
overall size of the analog in comparison to 1, but enhance the lipophilicity, electronegativity,
and overall inductive effects of the compound. This modification did not have a significant
impact on the binding and inhibition of CYP2A13, but interactions with CYP2A6 were
greatly affected as no spectral shift, consistent with no binding, and poor inhibition (Ki =
≥1000) was observed with 2, illustrating an increase in selectivity for CYP2A13.
Exchanging the fluorine atom for a chlorine atom (3) further enhanced the affinity and
inhibition for CYP2A13 resulting in low micromolar Kd (5.9 ± 3.4 μM) and Ki (39.7 ± 4.3
μM) values, but without any apparent binding to CYP2A6. Thus, this compound is highly
selective for CYP2A13. This same trend with selective binding and inhibition was observed
for the remaining ortho substituted compounds (4-6), which contained either electron
withdrawing or electron donating substituents. Compounds 4 and 6 were the most selective
inhibitors of CYP2A13 and were similar in both size and lipophilicity but varied in
electronic contributions from the substituent. These results illustrated that size and
lipophilicity at the ortho position may be more important than electronics in conferring
selective binding and inhibition of CYP2A13.
Disubstitution at the ortho position resulted in comparable Kd values or slight increases in
affinity for CYP2A13 over 3, with Kd values of 5.2 μM (7), 1.3 μM (8), and 1.1 μM (9),
while maintaining low micromolar inhibition with Ki values between 18.1 μM and 38.1 μM
with CYP2A13. While 7 did not cause a spectral shift at all with CYP2A6, compounds 8
and 9 demonstrated some binding to CYP2A6 with Kd values of ~500 μM but were still
>400-fold selective for binding to CYP2A13. Overall, the disubstituted compounds were not
as selective as the singly substituted compounds with regard to enzyme inhibition. For
CYP2A6, Ki values ranged from 237 μM to 296 μM, thus reducing the selectivity to 7.5- to
15-fold in comparison to ≥25-fold for (3). These results were interesting as CYP2A6 has an
overall smaller active site volume than CYP2A13(22) and did not demonstrate a spectral
shift with 7 and weakly bound 8 and 9, yet competitive inhibition was observed with
CYP2A6 and the larger disubstituted analogs. Thus, while disubstitution increased the
overall lipophilicity of the compound and maintained selective binding and inhibition of
CYP2A13, it enabled weak binding and inhibition of CYP2A6, perhaps via a small
conformational change in the CYP2A6 active site.
Meta and Para (C3 and C4) substitution on the benzyl ring
Single substitutions at the meta (10) and para (11) positions of the benzyl ring both
decreased affinity (Kd = 69.1 ± 30.2 μM (10), 168 ± 60.8 μM (11)) and inhibition (Ki = 260
μM (10), and 458 μM (11)) for CYP2A13 in comparison to the ortho position (3). As with
compound 1, definitive equilibrium dissociation constants could not be determined for 10
and 11 with CYP2A6, but weak spectral shifts are consistent with Kd values of ≥400 μM
(10) and ≥ 245 μM (11). Similarly both compounds weakly inhibited CYP2A6 with Ki
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values of 352 μM (10) and 448 μM (11). Evaluation of the binding and inhibition selectivity
ratios indicated that compounds 10 and 11 were not selective for either CYP2A enzyme.
However, disubstitution with a chlorine atom at the ortho position (12, 13) rescued
selectivity for CYP2A13 as illustrated by the inhibition results with an increase from ~1- to
~9-fold selectivity for CYP2A13, further demonstrating the importance of the ortho
substitution. Additional di-methyl substitution on the morpholine ring as shown in 14 had
minimal effects on Kd values, but this change had a greater effect in decreasing the
inhibition of both CYP2A13 and CYP2A6.
Ring Substitutions
Multiple ring analogs demonstrated a wide range of binding and inhibition constants. A
naphthalene substitution for benzene (15) weakly inhibited both CYP2A enzymes.
Replacing the morpholine ring with imidazole (16, 17) resulted in extremely potent but non-
selective analogs with submicromolar Kd and Ki values. Not surprisingly, the nitrogen of the
imidazole ring coordinated to the heme as demonstrated by the type II spectral shift.
Interestingly, both 16 and 17 were mixed inhibitors with low α values with CYP2A13, but
purely competitive inhibitors with CYP2A6. While the type II binding and potent inhibition
were anticipated for the imidazole compounds (16 and 17) due to the accessibility of the
nitrogen for coordination to the heme iron, it was unexpected to observe a type II spectral
shift for 18 with CYP2A6 (Kd = 154 μM) versus a type I spectral shift with CYP2A13 (Kd =
8.3 ± 4.1 μM). It is at present unknown as to which active site features resulted in the
distinct binding modes. Additionally, unlike the imidazole containing ligands, compound 18
was still selective for CYP2A13 with both binding (18-fold) and inhibition (8-fold).
The sulfur atoms in the thiophene rings of compounds 19 and 20 differed from 18 in that
only type I spectral shifts were observed for these compounds. The thiophene ring mimicked
a benzene ring, and it was expected that 19 and 20 would correlate with results from
compounds 1 and 3, respectively. Bioisosteric replacement of the benzene ring with a
thiophene ring, 19, increased the affinity and inhibition of CYP2A13 (Kd = 30.8 μM, Ki =
131 μM) over the parent compound, 1, but had similar results for CYP2A6 (Kd = ≥464 μM,
Ki = 270 μM). The ortho position of the sulfur may rationalize why 19 had a >3-fold
selectivity for CYP2A13 versus the parent compound (1) even though 19 had the same
spatial arrangement. As was observed for the parent compound, addition of a chlorine
substituent at the ortho position on the thiophene analog, 20, increased the selectivity for
CYP2A13 in both binding (22.3-fold) and inhibition (7.9-fold). This was achieved by
decreasing the equilibrium binding constant to 10.7 μM for CYP2A13 but did not
significantly impact the binding to CYP2A6 (Kd = ≥239 μM). Additionally, the chlorine
atom increased selectivity for CYP2A13 by reducing the Ki value to 54.7 μM (20) while
simultaneously decreasing inhibition of CYP2A6 (Ki = 433 μM).
The remaining ring analogs had a methylpiperazine ring in place of the morpholine ring (21,
22), which resulted in poor affinity and inhibition of both CYP2A enzymes as the Kd values
were ≥300 μM for CYP2A13 with weak or no spectral shifts with CYP2A6, and the Ki
values were ≥1000 μM. The weak interactions between 21 and 22 with the CYP2A enzymes
were due to either the disruption of optimal interactions within the active site and/or charge
addition. It was hypothesized that the methyl group could disrupt a hydrogen bond between
the nitrogen atom and N297, one of two polar residues within the active site. In addition,
incorporation of the methylpiperazine ring would have introduced a second positive charge
on the ligand at physiological pH. This charge may not have been well tolerated, resulting in
the poor binding and inhibition that was observed.
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Attachment of a methyl group to the one carbon linker (23) yielded a compound that
maintained comparable affinity and inhibition of CYP2A13 (Kd = 7.6 ± 2.8 μM, Ki = 15.9
μM) as 3, but decreased selectivity since 23 also bound and inhibited CYP2A6 (Kd = ≥538
μM, Ki = 98.5 μM). These trends were not observed with 24 when the linker was extended
to an ethyl group between the morpholine and benzene ring. Instead, a decrease in both
affinity and inhibition with the CYP2A enzymes was observed. Decreased affinity for
CYP2A13 could be due to the poor fit of the longer molecule within the active site, while
the methyl group on the linker in 23 did not significantly clash within the active site but
rather may have had additional van der Waals interactions with hydrophobic residues.
Compilation of the binding and inhibition studies has enabled the determination of
preliminary structure-activity relationships (SAR) for 4-benzylmorpholine-based agents
against CYP2A13 (Figure 2). We conclude that substitution at the ortho position of the
benzyl ring was the most vital feature of the benzylmorpholine scaffold, promoting selective
binding and inhibition of CYP2A13. Disubstitution at both ortho positions on the benzyl
ring slightly enhanced affinity for both CYP2A enzymes resulting in a reduction in the
selectivity for CYP2A13 versus the singly substituted analogs. Meta and para substitutions
on the benzyl ring, linkage extension between the rings, and exchange of the morpholine
ring for a methylpiperazine ring proved to be detrimental alterations in achieving selective
binding and inhibition for CYP2A13.
Toxicity and Metabolic Stability Evaluation
The in vitro results led to the conclusion that 4-benzylmorpholine analogs could selectively
inhibit CYP2A13. The next stage in the development of these analogs as potential
chemopreventative agents was the determination of toxicity and metabolic stability. First,
compounds 3 and 7, which represented both the singly and disubstituted compounds, were
evaluated for genetic and cardiac toxicity (Cerep, Redmond, WA). The Ames test was
employed to determine genetic toxicity, and few or no revertants were detected at compound
concentrations ranging from 5-100 μM. The potential of 3 and 7 to cause cardiac toxicity via
inhibition of the hERG channel was evaluated because this can be a major reason for drug
withdrawal or limitation. In a patch clamp assay, compounds 3 and 7 inhibited the tail
current by 13.9% and 24.8%, respectively, at the highest concentration tested, 10 μM. These
results suggest the hERG IC50 is >10 μM, placing the potency in the low category and
suggesting that toxicity associated with long QT intervals is unlikely to be arise from these
compounds.
The metabolic stability of 3 and 7 were evaluated with human, mouse, and rat lung and liver
microsomes over a 20-minute incubation (Xenotech, Overland Park, KS). Since the
CYP2A13 enzyme targeted by these inhibitors is located in the respiratory tract, it was
reassuring to observe that the benzylmorpholine analogs were very stable in human lung
microsomes with minimal or no loss of substrate observed (Table 2). However, under the
same conditions in human liver microsomes, at the end of 20 min only 53% or 14% of the
substrates (3 and 7, respectively) remained and in vitro T1/2 values of 22.9 and 7.6 minutes
were calculated. Corresponding in vitro intrinsic clearance values were 30.3 and 91.4 μl/
min/mg protein, respectively. Thus the 4-benzylmorpholine compounds are metabolized at
substantially different rates between tissues. Parallel evaluations from mouse and rat
microsomes indicated ≤3% compound remaining in either the lung or liver microsomes after
20 min. Thus 4-benzylmorpholine compounds are rapidly metabolized in mouse and rat lung
and liver and human liver microsomes, but persistent in human lung, the target tissue. This
data brought to light substantial differences in metabolic stability of the samples between
species and tissues, suggesting that dosing in human lung through inhalation would be
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optimal and that systematic exposure might be low due to rapid hepatic clearance. However,
these results also brought to light metabolic concerns over preclinical compound testing in
rat or mice model systems.
In an effort to determine the enzyme(s) likely to be involved in metabolism of these
compounds, compounds 3 and 7 (1 μM) were screened against a panel of the major human
xenobiotic metabolizing CYP enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4,
CYP2C19, and CYP2B6) and human liver microsomes (HLM) for in vitro half-life
determination (Table 3). The percent compound remaining was detected at 0, 5, 10, 20, 30,
and 45 minutes. The average in vitro half-life for the compounds ranged from <5 minutes
with CYP2B6 (3 and 7) to essentially no loss with CYP1A2 (3). CYP2B6 most quickly
reduced concentrations of benzylmorpholine compounds with 0% of both compounds
remaining after only 5 minutes. Substantial metabolism also occurred with CYP2C19 and to
a lesser extent CYP3A4 and CYP2C8.
The identification of CYP2B6 as a potentially significant component in rapid 4-
benzylmorpholine metabolism also suggested a possible rationale for the differences
between compound metabolic stability in mouse lung and human lung. While human lung
tissues have lower expression levels of the functional CYP2B enzyme, CYP2B6,(34) mice
have five CYP2B enzymes which might be active in the degradation of 4-benzylmorpholine
compounds. We tested this hypothesis by evaluating the metabolic stability of 7 in lung and
liver microsomes from knockout mice vs. wild type mice (Figure 3). These knockout mice
had a deletion of a DNA segment containing the genes coding for the CYP2A4, CYP2A5,
CYP2G1, CYP2S1, and all five CYP2B enzymes (Cyp2a(4/5)bgs mice) (35). It should be
noted that these experiments were performed with 1/10 the amount of protein (0.1 mg/ml) as
the studies above due to limited sample, so the clearance and t1/2 values can only be
compared with the side-by-side controls for wild type mice. In these transgenic mouse lung
microsomes metabolic stability of 7 was increased 5-fold compared to wild type lung
microsomes (in vitro t1/2 = 669 min vs. 124 min for wild type mice; in vitro intrinsic
clearance 10.4 vs. 55.7 for wild type mice). In liver microsomes from transgenic mice the
metabolic stability of 7 increased by 1.7-fold (in vitro t1/2 = 127 min vs. 73 minutes for wild
type mice; in vitro intrinsic clearance 54.8 vs. 95.3 for wild type mice). The increased
metabolic stability in the knockout mouse lung microsomes was more similar to the
metabolic stability in the human lung, suggesting the knockout mouse as an appropriate
model for preclinical studies of inhibitor effects on NNK bioactivation.
CONCLUSION
By altering various parts of the 4-benzylmorpholine small molecule scaffold, we were able
to identify the key structural aspects that contributed to the selective binding and inhibition
between the two closely related human CYP2A enzymes. This determination of structure-
activity relationships demonstrated that ortho-substituted 4-benzylmorpholine analogs have
the most promise as selective inhibitors of CYP2A13. Additionally testing for genetic and
cardio toxicities revealed no obstacles to further development and testing. Metabolic
stability testing demonstrated these compounds are stable in human lung microsomes but
would be rapidly cleared upon circulation, which would be expected to reduce systemic
exposure and any side effects. Administration through inhalation would reduce the first pass
effects while delivering the CYP2A13 inhibitors directly to the target tissue where they are
designed to block NNK bioactivation to carcinogens in tobacco users. While such a
chemopreventative agent would not be a replacement for tobacco cessation efforts, it could
be an effective complementary therapy to reduce the risk of lung cancer in tobacco users
who are unable, unwilling, or in the process of ceasing tobacco use. Identification of
CYP2A13-selective 4-benzylmorpholine compounds and an appropriate model system
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reflecting human lung lay the groundwork for pre-clinical in vivo testing of these
compounds.
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Identification of CYP2A13-specific ligands via high throughput screening. A. Distribution
of positive (PEITC) and negative (DMSO) controls. B. Scattergram of the UV/Vis spectral
shifts observed for 35,200 compounds in the screen. C. Schematic representation of
compound workflow. D. Identification of 4-benzylmorpholine scaffold as a specific ligand
for CYP2A13 vs. CYP2A6. While CYP2A13 (left) shows increasing absorbance changes in
response to ligand titration, no absorbance changes are observed upon titration with
CYP2A6 (right).
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Structure-activity relationships for the 4-benzylmorpholine scaffold with human CYP2A
enzymes.
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Metabolic stability of 7 in A) lung and B) liver microsomes generated from wild type and
transgenic CYP2A/CYP2B knockout mice.
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Table 1
Spectral equilibrium dissociation constants (Kd) and inhibition constants (Ki) for the benzylmorpholine library
with the human CYP2A6 and CYP2A13 enzymes, along with selectivity ratios for each.a
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Spectral shift notes: (I), Type I spectral shift; (II), Type II spectral shift; (I II), Change from type I to type II with a spectral shift at inhibitor
concentrations ≥300 μM; ≥ Minimal Kd value, except with 1 and 10 which had spectral shifts at ≥300 nm but no Kd value could be determined;
+
Kd value from average of duplicate samples with <4% variation, but an additional assay reported a value of 121 μM;
**
Evaluated concentrations greater than or equal to the maximum CYP2A13 concentration tested
d
Inhibition notes: (C), Competitive Inhibitor; (M), Mixed Inhibitor;
*
Outlier exclusion
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Table 2
Metabolic stability of compounds 3 and 7 with human, mouse, and rat lung and liver microsomes. Data for (3)
is in normal font, while data for (7) is in bold.
Species TestSystem








Liver 47.0/85.5 22.9/7.6 30.3/91.4
Lung No Loss/No Loss NA/NA NA/NA
Mouse
Liver 100/100 1.0*/0.8* 687/916
Lung 99.9/100 1.6*/1.3* 433/551
Rat
Liver 96.7/97.3 4.7*/4.0* 149/173
Lung 99.8/100 2.4*/1.5* 283/478
*
Values were less than the shortest incubation time and are therefore rough estimates
NA, Not applicable due to the lack of substrate depletion
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Table 3
Results for the average half-life of compounds 3 and 7 with a panel of human recombinant hepatic
cytochromes P450.
Compound Average T1/2 (min)
CYP1A2 CYP2C8 CYP2C9 CYP2D6 CYP3A4 CYP2C19 CYP2B6
3 2317 62 476 61 33 13 <5
7 1214 51 230 78 25 18 <5
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